Person:
Lampson, Lois

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Lampson

First Name

Lois

Name

Lampson, Lois
Author's Publications: search.filters.isAuthorOfPublication.0f3a46bd-160b-4680-a511-2beef6c8c0f4

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
  • Thumbnail Image
    Publication
    Monoclonal Antibodies in Neuro-Oncology
    (Landes Bioscience, 2011) Lampson, Lois
    Monoclonal antibodies (mAbs) are used with increasing success against many tumors, but for brain tumors the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is more complex. The BBB is closest to normal at micro-tumor sites; its properties and importance change as the tumor grows. In this review, evolving insight into the role of the BBB is balanced against other factors that affect efficacy or interpretation when mAbs are used against brain tumor targets. As specific examples, glioblastoma multiforme (GBM), primary central nervous system lymphoma (PCNSL) and blood-borne metastases from breast cancer are discussed in the context of treatment, respectively, with the mAbs bevacizumab, rituximab and trastuzumab, each of which is already widely used against tumors outside the brain. It is suggested that success against brain tumors will require getting past the BBB in two senses: physically, to better attack brain tumor targets, and conceptually, to give equal attention to problems that are shared with other tumor sites.
  • Thumbnail Image
    Publication
    Defining the Range of Cellular Components, Including Internal Antigens, That Can Serve as Targets of Graft Rejection
    (Hindawi Publishing Corporation, 1992) Lampson, M. A.; Dunne, A. D.; Lampson, Lois
    The mechanisms underlying rejection of grafted neural tissue are still being defined. Mechanisms relevant to genetically engineered cells are of current interest. To date, attention has focused on major histocompatibility complex (MHC) antigens as targets of graft rejection. Yet even when there is no MHC disparity, as when the patient's own cells are genetically altered, there is still a potential for graft rejection, directed against the novel antigens. We illustrate this in a rat model.
  • Thumbnail Image
    Publication
    Expression of Class I and II Major Histocompatibility Complex (MHC) Antigens in the Developing CNS
    (Hindawi Publishing Corporation, 1992) Grabowska, A.; Lampson, Lois
    The clinical potential of neural transplantation depends upon the feasibility of allogenenic or xenogeneic transplants, particularly of fetal tissue. This, in turn, is influenced by donor cell expression of MHC antigens. MHC expression in the developing CNS in situ had not been defined. Here, a panel of antibodies was used to define MHC expression in the developing rat embryo.